{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:55:15Z","timestamp":1781654115297,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,9]],"date-time":"2027-05-09T00:00:00Z","timestamp":1809820800000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ck0106028"],"award-info":[{"award-number":["JP25ck0106028"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cllc.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:42:48Z","timestamp":1776112968000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0082-9028","authenticated-orcid":false,"given":"Noriko","family":"Mitome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Yotsukura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-1027","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.04.006_bib0001","doi-asserted-by":"crossref","unstructured":"N.S.C.L.C. Meta-analyses Collaborative Group, R. Arriagada, A. Auperin, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data, Lancet. 375 (2010) 1267\u20131277. doi:10.1016\/s0140-6736(10)60059-1.","DOI":"10.1016\/S0140-6736(10)60059-1"},{"key":"10.1016\/j.cllc.2026.04.006_bib0002","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0004","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with Neoadjuvant Nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.006_bib0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.006_bib0006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"CheckMate 77T investigators, perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.006_bib0008","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial","volume":"41","author":"Spicer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0009","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.3390\/cancers13164035","article-title":"Perioperative therapy for non-small cell lung cancer with Immune checkpoint inhibitors","volume":"13","author":"Soh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0011","unstructured":"US Food and Drug Administration, FDA presentations: oncologic Drugs Advisory Committee Meeting, July 25, 2024. https:\/\/www.fda.gov\/media\/180308\/download, 2024 (accessed 8 October 2025)."},{"key":"10.1016\/j.cllc.2026.04.006_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0013","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jtho.2023.07.008","article-title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: an overview of the Central database informing revision of the forthcoming (Ninth) edition of the TNM Classification of malignant Tumors","volume":"18","author":"Rimner","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.cllc.2026.04.006_bib0015","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00595-015-1236-x","article-title":"Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria","volume":"46","author":"Katayama","year":"2016","journal-title":"Surg Today"},{"key":"10.1016\/j.cllc.2026.04.006_bib0016","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.006_bib0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2307\/2530299","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld","year":"1982","journal-title":"Biometrics"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:23:02Z","timestamp":1781652182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525730426000586"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}